Carbon C-14 Dacomitinib

A radioconjugate consisting of an orally bioavailable small-molecule inhibitor of the epidermal growth factor receptor (erbB or HER) family of tyrosine kinases radiolabeled with carbon-14 with potential antineoplastic and beta-emitting radioisotope activity. PF-00299804 specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors. The HER receptor family of tyrosine kinases, often overexpressed by a variety of tumor cell types, may contribute to tumor cell proliferation, differentiation, migration, and survival. PF-00299804 radiolabeled with carbon C-14 may be used as a radiotracer in pharmacological studies of PF-00299804 metabolism. (NCI Thesaurus)

YOU MAY ALSO LIKE

Carbon C-14

An unstable isotope of carbon created when a neutron collides with a nitrogen atom, causing capture of the neutron and release of…

Carbon C-13 Dextromethorphan

A radioconjugate consisting of dextromethorphan, a synthetic, methylated dextrorotatory analogue of levorphanol, conjugated with carbon-13 [(13)C] with radiotracer activity. (13)C-dextromethorphan can be…

Carbon C 14-labeled Ixazomib

A radioconjugate comprised of the orally available reversible 20S proteasome inhibitor ixazomib and labeled with the isotope carbon C 14. Upon administration,…

Carbon C 14 Telotristat Etiprate

An orally bioavailable, tryptophan hydroxylase (TPH) inhibitor prodrug labeled with carbon C 14, which could be used to evaluate the pharmacokinetic profile…

Carbon C 14 Selumetinib

A radioconjugate containing the orally available selumetinib, an inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) types 1 and 2,…

Carbon C 14 Oxaliplatin

A radioconjugate composed of the platinum agent oxaliplatin labeled with the isotope carbon C 14, that can be used to predict the…